Navigation Links
Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
Date:12/17/2007

Presentations Provide New Insights into Treatment Impact, Node-Positive

Breast Cancer, Measuring ER/PR Scores

REDWOOD CITY, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies reinforcing the clinical utility of the company's Oncotype DX(R), a multi-gene expression test to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients. This research was presented at the 30th Annual San Antonio Breast Cancer Symposium, December 13-15.

"The extensive body of research on Oncotype DX, including data presented in San Antonio this week, along with its recent inclusion in ASCO treatment guidelines, supports the use of Oncotype DX in treatment planning for women with early-stage estrogen receptor-positive breast cancer," said Lori J. Goldstein, M.D., Director of the Breast Evaluation Center at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and author of two Oncotype DX studies.

Eight studies presented at the San Antonio Breast Cancer Symposium evaluated Oncotype DX, including its use in estrogen receptor-positive, node- positive breast cancer; the test's impact on treatment selection and patient satisfaction; reporting of quantitative ER and PR scores within the Oncotype DX report; and a comparison between the Oncotype DX Recurrence Score(TM) and Adjuvant Online, among other presentations.

Positive Results in Node-Positive Disease

* An oral presentation by the Southwest Oncology Group (SWOG) on

Thursday, December 13 reported positive results for the Oncotype DX

Recurrence Score result in early-stage estrogen receptor
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider ... the Life Sciences sector, by setting up Intelent ... 3 million USD . Intelent aims to address the ... projections by McKinsey) by providing clients offerings in the areas ... Noting the exponential growth in ...
(Date:7/29/2015)... -- Touro College has announced that it is supporting ... five media marijuana licenses to be issued by the ... If CanniCare is selected, Touro would provide ... "Our college is supportive of medicinal development and research," said ... System. "There is still a great deal of research to ...
(Date:7/29/2015)... 2015  Cepheid (Nasdaq: CPHD ) today ... Xpert® Carba-R, with the addition of two newly ... molecular test also detects and differentiates among the ... KPC, NDM, VIM, IMP-1 and OXA-48. ... Superbugs, are a growing and expensive challenge for ...
Breaking Medicine Technology:TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 2TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 3Touro College Announces Support for CanniCare's Medical Cannabis License Application 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4
... 3, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect ... principal amount of senior unsecured notes (the "Notes"). ... Securities Act of 1933, as amended (the "Securities Act"), ...
... Feb. 3, 2011 Unilife Corporation ("Unilife" or the "Company") ... it has appointed Dr. Ramin Mojdeh, formerly Vice President and ... and Worldwide Vice President of Research and Development, BD Medical, ... effective February 7, 2011. Dr. Mojdeh comes ...
Cached Medicine Technology:Valeant Launches Senior Notes Offering 2Valeant Launches Senior Notes Offering 3Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 2Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 3Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 4Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 5
(Date:7/29/2015)... ... July 29, 2015 , ... On ... regulations imposed by the FDA for nicotine laced liquid products. Their report says ... have raised considerably. E-Cigarettes are particularly troublesome to addiction professionals as many of ...
(Date:7/29/2015)... ... July 29, 2015 , ... Orthopedic surgeons at Lourdes Medical ... Rotation Medical Rotator Cuff System, a new implant to treat a common source of ... foster natural regeneration of additional tendon tissue, which could allow for faster healing and ...
(Date:7/29/2015)... , ... July 29, 2015 , ... CanAm Enterprises, LLC ... USCIS over the past month! I-829 approvals have been granted to investors in four ... Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center ...
(Date:7/29/2015)... ... ... It is unique for a health center to dedicate a full-time medical ... is very hands on and resident oriented, and one to which Dr. Rennecker is ... and energy, as well as a strong commitment to helping seniors live longer, healthier ...
(Date:7/29/2015)... ... , ... Attorneys representing American families in national talcum powder lawsuits announce the ... a page dedicated to news related to pending talcum powder lawsuits, as well as ... News page was launched with eight initial articles. , “We decided to add ...
Breaking Medicine News(10 mins):Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 3
... insulin resistance and high blood pressure begin as early ... measured obesity, insulin resistance, blood pressure and cholesterol levels ... the young people were 13 and again when they ... mass index (BMI) calculation. BMI is the person's weight ...
... is being tested against cervical cancer. Human papilloma virus ... but not everyone with the virus develops the cancer. ... and causes 300,000 deaths. If it is diagnosed and ... survival rate. // ,Doctors at Britain's Cancer ...
... body to the ageing process and may increase the ... and diabetes, researchers have found. ,These days, the average ... more developed countries has decreased from nine hours to ... increased demands of work and more leisure activities. ...
... who work nightshifts are more prone to develop breast cancer. ... worked during the nights for up to three years were ... did not work at night. ,And the risk increased to ... three years. ,The results of the study, carried ...
... Women who have irregular or very long menstrual cycles ... such menstrual abnormalities needn't panic because the risk can ... exercise and weight control. // ,Menstrual cycles ... be markers for some sort of underlying metabolic abnormality. ...
... study, cycling has shown a beneficial effect in treating sexual ... produce sexual dysfunction in men because blood flow is restricted, ... an erection. The problem is that many of these men ... medication for heart failure. ,Researchers in France reported ...
Cached Medicine News:Health News:Heart disease starts early 2Health News:Deprived sleep leads to ageing 2
... System is a latex-free unisex system ... simple catheterization designed to reduce the ... It includes a 100% latex-free Mentor ... tear tab makes it easy to ...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: